1-2 of 2
Michel Meignan
Close
Sort by
Journal Articles

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma

Clinical Trials & Observations
François Lemonnier, Violaine Safar, Asma Beldi-Ferchiou, Anne-Ségolène Cottereau, Emmanuel Bachy, Guillaume Cartron, Virginie Fataccioli, Laura Pelletier, Cyrielle Robe, Audrey Letourneau, Edoardo Missiaglia, Slim Fourati, Marie-Pierre Moles-Moreau, Alain Delmer, Reda Bouabdallah, Laurent Voillat, Stéphanie Becker, Céline Bossard, Marie Parrens, Olivier Casasnovas, Victoria Cacheux, Caroline Régny, Vincent Camus, Marie-Hélène Delfau-Larue, Michel Meignan, Laurence de Leval, Philippe Gaulard, Corinne Haioun
Journal: Blood Advances
Blood Adv (2021) 5 (2): 539–548.
https://doi.org/10.1182/bloodadvances.2020003081
Published: 2021
Includes: Supplemental data
Journal Articles

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Laetitia Vercellino, Roberta Di Blasi, Salim Kanoun, Benoit Tessoulin, Cedric Rossi, Maud D'Aveni-Piney, Lucie Obéric, Caroline Bodet-Milin, Pierre Bories, Pierre Olivier, Ingrid Lafon, Alina Berriolo-Riedinger, Eugenio Galli, Sophie Bernard, Marie-Thérèse Rubio, Celine Bossard, Veronique Meignin, Pascal Merlet, Pierre Feugier, Steven Le Gouill, Loic Ysebaert, Olivier Casasnovas, Michel Meignan, Sylvie Chevret, Catherine Thieblemont
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5607–5615.
https://doi.org/10.1182/bloodadvances.2020003001
Published: 2020
Includes: Supplemental data